Safety check: does a rare disease drug harm the liver?
NCT ID NCT07293897
Summary
This study aims to understand the risk of liver problems in Japanese children taking Livmarli for two rare liver diseases, Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC). Researchers will use an existing medical database to track about 50 patients who have been prescribed the drug. The main goal is to see how often and how quickly liver issues occur while using this medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALAGILLE SYNDROME (ALGS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Takeda selected site
RECRUITINGTokyo, Tokyo, Japan
Conditions
Explore the condition pages connected to this study.